ASKA Pharmaceuticals' market cap is covered 30% by net non-operating assets that render its EV/EBITDA multiple too low for a growing generics business in Japan. It has a growing exposure to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results